Patient-reported outcomes in core domain sets for rheumatic diseases

Nature Reviews Rheumatology

Volumn 11, Issue 12, 2015, Pages 705-712

  Van Tuyl, Lilian H D ^a   Boers, Maarten ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; BEHCET DISEASE; CHILD HEALTH QUESTIONNAIRE; CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; EVIDENCE BASED PRACTICE; FIBROMYALGIA; FUNCTIONAL ASSESSMENT; GOUT; GOUT ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEALTH STATUS; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING; JUVENILE RHEUMATOID ARTHRITIS; LIKERT SCALE; MUSCULOSKELETAL DISEASE ASSESSMENT; MYOSITIS; OSTEOARTHRITIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT REPORTED OUTCOME; PEDIATRIC QUALITY OF LIFE INVENTORY; PRIORITY JOURNAL; PRO MEASUREMENT INFORMATION SYSTEM; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS IMPACT OF DISEASE QUESTIONNAIRE; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS IMPACT OF DISEASE QUESTIONNAIRE; ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3; SCORING SYSTEM; SELF REPORT; SHORT FORM 36; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS SPECIFIC QUALITY OF LIFE INSTRUMENT; VASCULITIS; VISUAL ANALOG SCALE; RHEUMATIC DISEASES; SELF EVALUATION;

DIAGNOSTIC SELF EVALUATION; HUMANS; RHEUMATIC DISEASES;

EID: 84948714278     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.116     Document Type: Review

References (87)

1. Wells, G., Li, T., Maxwell, L., Maclean, R.,&Tugwell, P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann. Rheum. Dis. 67, 260-265 (2008
2. Minnock, P., Kirwan, J.,&Bresnihan, B. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology (Oxford) 48, 1533-1536 (2009
3. Minnock, P., Kirwan, J., Veale, D., FitzGerald, O.,&Bresnihan, B. Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. Clin. Exp. Rheumatol. 28, 401-404 (2010
4. Hazes, J. M., et al. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 49, 1900-1910 (2010
5. Sokka, T., Hakkinen, A., Krishnan, E.,&Hannonen, P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann. Rheum. Dis. 63, 494-497 (2004
6. de Wit, M. P., et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann. Rheum. Dis. 70, 722-726 (2011
7. de Wit, M., Abma, T., Koelewijn-Van, L. M., Collins, S.,&Kirwan, J. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. BMJ Open 3, e002241 (2013
8. Kirkham, J. J., Boers, M., Tugwell, P., Clarke, M.,&Williamson, P. R. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials 14, 324 (2013
9. OMERACT. Outcome Measures in Rheumatology [online], http://www.omeract.org/omeract-publications.html (2015
10. ACR. American College of Rheumatology [online], http://www.rheumatology.org/Practice/Clinical/Clinical-Support/(2015
11. EULAR. The European League Against Rheumatism [online], http://www.eular.org/recommendations-conducting-reporting-clinical-trials.cfm (2015
12. COMET Initiative. Core Outcome Measures in Effectiveness Trials [online], http://www.comet-initiative.org/(2015
13. Boers, M., et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J. Rheumatol. Suppl. 41, 86-89 (1994
14. Aletaha, D., et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann. Rheum. Dis. 67, 1360-1364 (2008
15. Bykerk, V. P., et al. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare workshop. J. Rheumatol. 41, 799-809 (2014
16. Wells, G. A., et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J. Rheumatol. 32, 2016-2024 (2005
17. Felson, D. T., et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis. 70, 404-413 (2011
18. Felson, D. T., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 36, 729-740 (1993
19. Tugwell, P.,&Boers, M. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. J. Rheumatol. 20, 555-556 (1993
20. Pincus, T., Yazici, Y.,&Bergman, M. J. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum. Dis. Clin. North Am. 35, 773-778 (2009
21. Kirwan, J. R., et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J. Rheumatol. 34, 1174-1177 (2007
22. Gossec, L., et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann. Rheum. Dis. 68, 1680-1685 (2009
23. Gossec, L., et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann. Rheum. Dis. 70, 935-942 (2011
24. Lie, E., et al. Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. Ann. Rheum. Dis. 73, 1781-1787 (2013
25. van Tuyl, L. H., et al. The patient perspective on remission in rheumatoid arthritis: Youve got limits, but youre back to being you again. Ann. Rheum. Dis. 74, 1004-1010 (2014
26. Orbai, A. M., Smith, K. C., Bartlett, S. J., De Leon, E.,&Bingham, C. O. 3rd. Stiffness has different meanings, I think, to everyone. Examining stiffness from the perspective of people living with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66, 1662-1672 (2014
27. Hoving, J. L., van Zwieten, M. C., van der Meer, M., Sluiter, J. K.,&Frings-Dresen, M. H. Work participation and arthritis: a systematic overview of challenges, adaptations and opportunities for interventions. Rheumatology (Oxford) 52, 1254-1264 (2013
28. Tang, K., et al. Worker productivity outcome measures: OMERACT filter evidence and agenda for future research. J. Rheumatol. 41, 165-176 (2014
29. Flurey, C. A., Morris, M., Richards, P., Hughes, R.,&Hewlett, S. Its like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimes. Rheumatology (Oxford) 53, 696-703 (2014
30. Stack, R. J., et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: a qualitative exploration of symptom development. Rheumatology (Oxford) 53, 1646-1653 (2014
31. Gerlag, D. M., et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann. Rheum. Dis. 71, 638-641 (2012
32. Sieper, J., et al. The Assessment of Spondyloarthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 68 (Suppl. 2), 1-44 (2009
33. van der Heijde, D., et al. Which domains should be included in a core set for endpoints in ankylosing spondylitis?. Introduction to the ankylosing spondylitis module of OMERACT IV. J. Rheumatol. 26, 945-947 (1999
34. Anderson, J. J., Baron, G., van der Heijde, D., Felson, D. T.,&Dougados, M. Ankylosing spondylitis assessment group preliminary definition of short-Term improvement in ankylosing spondylitis. Arthritis Rheum. 44, 1876-1886 (2001
35. Lukas, C., et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68, 18-24 (2009
36. Gottlieb, A. B., et al. The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting. J. Rheumatol. 41, 1227-1229 (2014
37. Gladman, D. D., et al. Consensus on a core set of domains for psoriatic arthritis. J. Rheumatol. 34, 1167-1170 (2007
38. Gossec, L., et al A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann. Rheum. Dis. 73, 1012-1019 (2014
39. Singh, J. A., et al. OMERACT endorsement of measures of outcome for studies of acute gout. J. Rheumatol. 41, 569-573 (2014
40. Singh, J. A., et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J. Rheumatol. 38, 1452-1457 (2011
41. Colwell, H. H., et al. Gout Assessment Questionnaire: initial results of reliability, validity and responsiveness. Int. J. Clin. Pract. 60, 1210-1217 (2006
42. Gaffo, A. L., et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 64, 1508-1517 (2012
43. Bellamy, N., et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J. Rheumatol. 24, 799-802 (1997
44. Altman, R., et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartil. 4, 217-243 (1996
45. Conaghan, P. G., Kloppenburg, M., Schett, G.,&Bijlsma, J. W. Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee. Ann. Rheum. Dis. 73, 1442-1445 (2014
46. Kloppenburg, M., et al. Report from the OMERACT hand osteoarthritis special interest group: advances and future research priorities. J. Rheumatol. 41, 810-818 (2014
47. Smolen, J. S., et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J. Rheumatol. 26, 504-507 (1999
48. Strand, V., et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J. Rheumatol. 26, 490-497 (1999
49. Mosca, M., et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann. Rheum. Dis. 69, 1269-1274 (2010
50. Gordon, C., et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann. Rheum. Dis. 68, 470-476 (2009
51. van Vollenhoven, R. F., et al. Treat to target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 73, 958-967 (2014
52. Dua, A. B., Touma, Z., Toloza, S.,&Jolly, M. Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Curr. Rheumatol. Rep. 15, 380 (2013
53. Kiani, A. N.,&Petri, M. Quality of life measurements versus disease activity in systemic lupus erythematosus. Curr. Rheumatol. Rep. 12, 250-258 (2010
54. Castrejón, I., et al A freely accessible toolbox for patient-reported outcomes: development and systematic literature review for lupus instruments [abstract]. Arthritis Rheum. 65 (Suppl. 10), 2520 (2013
55. Castrejón, I., Gossec, L.,&Carmona, L. The EULAR outcome measures library: an evolutional database of validated patient-reported instruments. Ann. Rheum. Dis. 74, 475-476 (2015
56. Boers, M., et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J. Clin. Epidemiol. 67, 745-753 (2014
57. Merkel, P. A., et al. Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. J. Rheumatol. 36, 2362-2368 (2009
58. Merkel, P. A., et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-Associated vasculitis. J. Rheumatol. 38, 1480-1486 (2011
59. Herlyn, K., Hellmich, B., Seo, P.,&Merkel, P. A. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res. (Hoboken) 62, 1639-1645 (2010
60. Hatemi, G., et al. Outcome measures used in clinical trials for Behçet syndrome: a systematic review. J. Rheumatol. 41, 599-612 (2014
61. Khanna, D., et al. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J. Rheumatol. 36, 2356-2361 (2009
62. Wolfe, F., et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. (Hoboken) 62, 600-610 (2010
63. Mease, P., et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J. Rheumatol. 36, 2318-2329 (2009
64. Mease, P. J., et al. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J. Rheumatol. 38, 1487-1495 (2011
65. Sambrook, P. Guidelines for osteoporosis trials. J. Rheumatol. 24, 1234-1236 (1997
66. Hiligsmann, M., et al. Patients preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res. Ther. 16, R36 (2014
67. Fraenkel, L., Gulanski, B.,&Wittink, D. Patient treatment preferences for osteoporosis. Arthritis Rheum. 55, 729-735 (2006
68. Giannini, E. H., et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 40, 1202-1209 (1997
69. Heiligenhaus, A., et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-Associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res. (Hoboken) 64, 1365-1372 (2012
70. Ruperto, N., et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken) 62, 1542-1551 (2010
71. Ruperto, N., et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 42, 1452-1459 (2003
72. Miller, F. W., et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40, 1262-1273 (2001
73. Alexanderson, H., et al. Patient-reported outcomes and adult patients disease experience in the idiopathic inflammatory myopathies. Report from the OMERACT 11 myositis special interest group. J. Rheumatol. 41, 581-592 (2014
74. Mackie, S. L., et al. Polymyalgia rheumatica (PMR) special interest group at OMERACT 11: outcomes of importance for patients with PMR. J. Rheumatol. 41, 819-823 (2014
75. Furu, M., et al. Discordance and accordance between patients and physicians assessments in rheumatoid arthritis. Scand. J. Rheumatol. 43, 291-295 (2014
76. Kaneko, Y., Kuwana, M., Kondo, H.,&Takeuchi, T. Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment. J. Rheumatol. 41, 1061-1066 (2014
77. Khan, N. A., et al. Determinants of discordance in patients and physicians rating of rheumatoid arthritis disease activity. Arthritis Care Res. (Hoboken) 64, 206-214 (2012
78. Steinbrocker, O.,&Blazer, A A therapeutic score card for rheumatoid arthritis; a standardized method of appraising results of treatment. N. Engl. J. Med. 235, 501-506 (1946
79. Khan, N. A., et al. Patients global assessment of disease activity and patients assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. Ann. Rheum. Dis. 71, 1942-1949 (2012
80. van Tuyl, L. H.,&Boers, M. Patients global assessment of disease activity: what are we measuring?. Arthritis Rheum. 64, 2811-2813 (2012
81. Dandorfer, S. W., Rech, J., Manger, B., Schett, G.,&Englbrecht, M. Differences in the patients and the physicians perspective of disease in psoriatic arthritis. Semin. Arthritis Rheum. 42, 32-41 (2012
82. Studenic, P., Radner, H., Smolen, J. S.,&Aletaha, D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 64, 2814-2823 (2012
83. WHO. Towards a common language for functioning, disability and Health. ICF: the International Classification of Functioning, Disability and Health. World Health Organization [online], http://www.who.int/classifications/icf/training/icfbeginnersguide.pdf (2002
84. NIH. PROMIS: Dynamic tools to measure health outcomes from the patients perspective [online], http://www.nihpromis.org/(2015
85. Khanna, D., et al. The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS). Arthritis Care Res. (Hoboken) 63 (Suppl. 11), S486-S490 (2011
86. Kalyoncu, U., Dougados, M., Daures, J. P.,&Gossec, L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 68, 183-190 (2009
87. Bautista-Molano, W., et al. How well are the ASAS/OMERACT core outcome sets for ankylosing spondylitis implemented in randomized clinical trials? A systematic literature review. Clin. Rheumatol. 33, 1313-1322 (2014